The structures and inhibitory effects of Buame [N-(3-hydroxy-1,3,5(10)- estratrien-17β-yl)-butylamine] and Diebud [N,N′-bis-(3-hydroxy-1,3, 5(10)-estratrien-17β-yl)-1,4-butanediamine] on platelet aggregation

Steroids

Volumn 77, Issue 5, 2012, Pages 512-520

  Flores García, Mirthala ^a,d   Fernández G, Juan M ^c   León Martínez, Mireille ^c   Hernández Ortega, Simón ^c   Pérez Méndez, Oscar ^a   Correa Basurto, José ^d   Carreón Torres, Elizabeth ^a   Tolentino López, Luis E ^d   Ceballos Reyes, Guillermo Manuel ^d   De La Peña Díaz, Aurora ^a,b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Aminoestrogen; Buame; Diebud; Platelet inhibition

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; BUAME; COLLAGEN; DIEBUD; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DOCKING; RECEPTOR BINDING; SPECTROPHOTOMETRY; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADULT; BINDING SITES; COLLAGEN; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL CONGENERS; ESTROGEN RECEPTOR ALPHA; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; YOUNG ADULT;

EID: 84858339324     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.01.010     Document Type: Article

References (48)

1. United Nations Department of Economic and Social Affairs. World contraceptive use. 2007.
2. Center for Disease Control and Prevention (CDC) US medical eligibility criteria for contraceptive use MMWR Recomm Rep 59 RR-4 2010 1 86
3. A. van Hylckama Vlieg, and S. Middeldorp Hormone therapies and venous thromboembolism: where are we now? J Thromb Haemost 9 2011 257 266
4. V. Olié, M. Canonico, and P.Y. Scarabin Postmenopausical hormone therapy and venous thromboembolism Thromb Res 127 Suppl 3 2011 S26 9
5. O. Lidegaard, E. Lokkegaard, A.L. Svendsen, and C. Agger Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 2009 b2890
6. A. van Hylckama Vlieg, F.M. Helmerhorst, J.P. Vandenbroucke, C.J. Doggen, and F.R. Rosendaal The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study BMJ 339 2009 b2921
7. R. Reid, N. Leyland, W. Wolfman, C. Allaire, A. Awadalla, and C. Best Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines: Oral contraceptives and the risk of venous thromboembolism: an update: no. 252, December 2010 Int J Gynaecol Obstet 112 3 2011 252 256
8. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, and H. Black Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712 (Pubitemid 38489892)
9. S.N. Tchaikovski, and J. Rosing Mechanisms of estrogen-induced venous thromboembolism Thromb Res 126 1 2010 5 11
10. P. Gaussem, M. Alhenc-Gelas, J.L. Thomas, C. Bachelot-Loza, V. Remones, and F.D. Ali Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomized study Thromb Haemost 105 3 2011 560 567
11. E. Daly, M.P. Vessey, M.M. Hawkins, J.L. Carson, P. Gough, and S. Marsh Risk of venous thromboembolism in users of hormone replacement therapy Lancet 348 1996 977 980 (Pubitemid 26340751)
12. M.E. Mendelsohn, and R.H. Karas Estrogen and the blood vessel wall Curr Opin Cardiol 9 1994 619 626 (Pubitemid 24267789)
13. S.S. Smyth, R.P. McEver, A.S. Weyrich, C.N. Morrell, M.R. Horrman, and G.M. Arepally Platelet Colloquium Participants. Platelet functions beyond hemostasis J Thromb Haemost 7 11 2009 1759 1766
14. A. Roell, P. Schueller, A. Schultz, R. Losel, M. Wehling, and M. Christ Effect of oral contraceptives and ovarian cycle on platelet function Platelets 18 2 2007 165 170 (Pubitemid 46398999)
15. G. Khetawat, N. Faraday, M.L. Nealen, K.V. Vijayan, E. Bolton, and S.J. Noga Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression Blood 95 7 2000 2289 2296 (Pubitemid 30167727)
16. M. Jayachandran, and V.M. Miller Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins Platelets 14 2 2003 75 81 (Pubitemid 36461463)
17. G.G. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Häggblad, and S. Nilsson Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta Endocrinology 138 3 1997 863 870 (Pubitemid 27089735)
18. T.C. Pappas, B. Gametchu, and C.S. Watson Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding FASEB J 9 5 1995 404 410
19. C.S. Watson, C.H. Campbell, and B. Gametchu The dynamic and elusive membrane estrogen receptor-α Steroids 67 2002 429 437 (Pubitemid 34311757)
20. R. Marin, B. Guerra, R. Alonso, C.M. Ramírez, and M. Díaz Estrogen activates classical and alternative mechanisms to neuprotection Curr Neuvasc Res 2 4 2005 287 301 (Pubitemid 41297367)
21. E. Murphy Estrogen signaling and cardiovascular disease Circ Res 109 6 2011 687 696
22. G.J. Wu, J.J. Le, D.S. Chou, T. Jayakumar, G. Hsiao, and W.F. Chen Inhibitory signaling of 17β-estradiol in platelet activation: the pivotal role of cyclic AMP- mediated nitric oxide synthase activation Eur J Pharmacol 649 1-3 2010 140 149
23. L. Moro, S. Reineri, D. Piranda, D. Pietrapiana, P. Lova, and A. Bertoni Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase Blood 105 1 2005 115 121 (Pubitemid 40053072)
24. A. De la Peña, G. Baños, R. Izaguirre, J.J. Mandoki, and J.M. Fernández Comparative effect of synthetic aminoestrogens with estradiol on platelet aggregation Steroids 58 9 1993 407 409
25. P. Akarasereenont, P. Tripatara, S. Chotewuttakorn, T. Palo, and A. Thaworn The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate Platelets 17 2006 441 447 (Pubitemid 44665566)
26. G.M. Sheldrick SHELXS-97. Program for Crystal Structure Solution. Version 97-1 1997 Institut Anorg. Chemie., University of Gottingen Germany
27. G.M. Sheldrick SHELXL-97. Program for Crystal Structure Refinement. Version 97-1 1997 Institut Anorg. Chemie., University of Gottingen Germany
28. A.J.C. Wilson International Tables for Crystallography 1992 Kluwer Academic Publishers Dordrecht [C:583-4]
29. J.M. Fernández-G, M.F. Rubio-Arroyo, M. Soriano-García, R.A. Toscano, and C. Rubio-Póo Synthesis and molecular structure of prolame, N-(3-hydroxy-1,3,5(10)-estratrien-17β-yl)-3-hydropropylamine; an amino-estrogen with prolonged anticoagulant and brief estrogen effects Steroids 45 1985 151 157
30. Y. Marín, R. Fernández-Mas, A. Cuellar, A. de la Peña, J.M. Fernández-G, and G. Baños Uterotropic activity and effect on the contractility of the isolated rat myometrium of three synthetic alkanol-amino estrogens: etolame, buolame and pentolame Med Sci Res 24 1996 247 249
31. J.J. Mandoki, C. Rubio-Póo, C. Lemini, A. de la Peña, J.M. Fernández-G, and J. García-Mondragón Proc West Pharmacol Soc 34 1991 99 106
32. M.J. Frisch MJ, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, and J.R. Cheeseman Gaussian 98, Revision A.9. 1998 Gaussian, Inc. Pittsburgh
33. R. Huey, G.M. Morris, A.J. Olson, and D.S. Goodsell A semiempirical free energy force field with charge-based desolvation J Comput Chem 28 6 2007 1145 1152 (Pubitemid 46506716)
34. O. Pérez-Méndez, P. Alvarez-Salcedo, E. Carreón Torres, G. Luc, M. Arce Fonseca, and A. de la Peña Clin Chim Acta 378 1-2 2007 53 58
35. C. Lemini, R. Jaimez, and R.A. Toscano Confirmation of the C-17 stereochemistry of pentolame by single crystal X-ray analysis of its monohydrate Rev Soc Quim Mex 48 2004 256 259
36. P.B. Busetta, and M. Hospital Structure Cristalline et Moléculaire de l'Oestradiol Memihydrate Acta Cryst B B28 1972 560 567
37. C. Lemini, E. Cruz-Ramos, R.A. Toscano, and R. Cruz-Almanza A comparative structural study of the steroid epimers: 17 beta-amino-1,3,5(10)-estratrien-3- ol, 17 alpha-amino-1,3,5(10)-estratrien-3-ol, and some derivatives by 1H NMR, and x-ray diffraction analysis Steroids 63 11 1998 556 564 (Pubitemid 28525423)
38. F.H. Allen, O. Kennard, D.G. Watson, L. Brammer, and A.G. Orpen Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds J Chem Soc Perkin Trans 2 1987 S1 19
39. Moreno-Vargas L, Correa-Basurto J, Maroun RC, Fernández FJ. Homology modeling of the structure of acyl coA:isopenicillin N-acyltransferase (IAT) from Penicillium chrysogenum. IAT interaction studies with isopenicillin-N, combining molecular dynamics simulations and docking. J Mol Model, in Press. doi:10.1007/s00894-011-1143-z.
40. Gupta P, Durani S. Aromatic interactions at atom-to-atom contact and just beyond: a case study of protein interactions of NAD(+)/NADP(+). Int J Biol Macromol, in Press. doi:10.1016/j.ijbiomac.2011.08.025.
41. D.A. Dougherty, and D.A. Stauffer Acetylcholine binding by synthetic receptor: implications for biological recognition Science 250 4987 1990 1558 1560 (Pubitemid 120034365)
42. C. Lin, R. Chinnappan, K. Acharya, J.L. Pellequer, and R. Jankowiak On stabilization of a neutral aromatic ligand by π-cation interactions in monoclonal antibodies Biophys Chem 154 1 2011 35 40
43. D.M. Tanenbaum, Y. Wang, S.P. Williams, and P.B. Sigler Crystallographic comparison of the estrogen receptor's ligand binding domains Proc Natl Acad Sci U S A 95 11 1998 5998 6003 (Pubitemid 28248953)
44. G.M. Anstead, K.E. Carlson, and J.A. Katzenellenbogen The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor bindingsite Steroids 62 3 1997 268 303 (Pubitemid 27114399)
45. A. De la Peña, M. Flores, B. Valente-Acosta, L. Quintanar-Trejo, C. Hernández-Méndez, and S. Muñoz-Martínez Platelet aggregation in whole blood, a new approach for understanding the antiplatelet effect on N-(3-Hydroxy-1,3,5(10)-estratien-17b-yl) Butylamine (Buame) Proc West Pharmacol Soc 52 2009 50 53
46. M. Jayachandran, R. Mukherjee, T. Steinkamp, P. LaBreche, M.P. Bracamonte, and H. Okano Differential effects of 17beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets Am J Physiol Heart Circ Physiol 288 5 2005 H2355 62
47. C.J. Lowenstein, and H. Tsuda N-Ethylmaleimide-sensitive factor: a redox sensor in Exocytosis Biol Chem 387 2006 1377 1383 (Pubitemid 44691418)
48. G. González, N. Alvarado-Vásquez, J.M. Fernández-G, D. Cruz-Robles, L. Del Valle, and E. Pinzón The antithrombotic effect of the aminoestrogen prolame (N-(3-hydroxy-1,3,5(10)-estratrien-17B-YL)-3- hydroxyprolamine) is linked to an increase in nitric oxide production bu platelet and endothelial cells Atherosclerosis 208 1 2010 62 68